




REBOUND COVID-19 AFTER PAXLOVID IN 2 RELATED FAMILY MEMBERS



PETRICK PERIYASAMY¹ | TAN LI FEN¹ | NAJMA KORI¹ | UMMU AFEERA ZAINULABID^{1,2}




Intro




On May 24, 2022, the CDC issued a healthcare advisory after reports of COVID-19 symptoms returning (COVID-19 rebound) in certain patients two to eight days after treatment with Paxlovid (Ritonavir-Boosted Nirmatrevir). We described two patients who experienced a rebound of COVID-19 after receiving Paxlovid treatment.

Methods




We described a case series involving a 67-year-old father and his 37-year-old daughter who developed high-grade fever with chills and rigors, myalgia, arthralgia, sore throat, rhinorrhea, and non-chesty cough. Both tested for COVID-19 RTK Ag which resulted in a positive test. They went to the primary care clinic on day 2 of illness and were prescribed oral Paxlovid therapy for five days. Symptoms significantly resolved during the treatment and repeated self-tested COVID-19 RTK Ag saliva test on day 4 of treatment yielded a negative result.

Conclusion




More study is required to describe the host and predisposing genetic characteristics that can aid in recognizing and understanding the phenomenon. In addition, more investigation is needed to evaluate the severity and clinical characteristics of these patients and to identify the underlying reason.

Findings



On day 9 of illness (Day 3 completion of Paxlovid), both patients developed rebound respiratory symptoms with anosmia. With the doubt of suddenly developing recurrent symptoms with new onset anosmia, they decided to repeat the RTK Ag test, which resulted in positive results. Therefore, they were treated as rebound COVID-19 post-Paxlovid treatment. Symptomatic treatments were given and they were advised for home quarantine.

Discussion



Based on the illustration of the case, the diagnosis dilemma exists whether this is the progression of the disease, rebound phenomena, or re-infection. However, given the brief period in between presentations, rebound COVID-19 post-Paxlovid is likely. In rebound COVID-19, there was no need for other antiviral medication due to the moderate nature of the symptoms experienced by those mentioned.

Fwd: ISID 2022 - Poster Acceptance

Petrick Periyasamy <petrick.periyasamy@gmail.com>
To: UMMU AFEERA BINTI ZAINULABID . <ummuafeera@iium.edu.my>

Wed, 5 Oct, 1:08 PM

----- Forwarded message -----
From: **ISID** <noreply@ctimeetingtech.com>
Date: Sun, Oct 2, 2022 at 6:26 PM
Subject: ISID 2022 - Poster Acceptance
To: Petrick Periyasamy <petrick.periyasamy@gmail.com>



Dear Dr. Petrick Periyasamy,

We thank you for your interest in the forthcoming **International Congress on Infectious Diseases (ISID 2022)** to be held **17-20 November in Kuala Lumpur, Malaysia**.

On behalf of the Scientific Program Committee, we are delighted to confirm that your abstract has been selected for a **Poster**.

Please see your details:

Abstract Number: 608
Abstract Title: REBOUND COVID-19 AFTER PAXLOVID IN 2 RELATED FAMILY MEMBERS
Presenting Author: Petrick Periyasamy

Further information on how to prepare your Poster will be sent to you in due course.

Please note that the program is a subject to change. We recommend visiting the Congress [website](#) regularly for any updates or changes to the scientific program.

CONFIRMATION OF ATTENDANCE AND REGISTRATION TO THE CONGRESS

The presenting author must confirm his/her attendance by registering for the Congress by **October 7, 2022**.

In case you are unable to present the abstract, please indicate which co-author will do so. This person will have to register for the Congress.

If you have not already registered and paid your registration fee, you are requested to do so online via this [link](#). **Please note:** Only abstracts of presenters who have registered and paid their fees by the above deadline will be included in the final congress program.

Please disregard the above step if you have an existing registration or have paid a registration fee. Your registration has been automatically renewed.

In case you are registering for the Congress as part of a group, please let us know the group name and organiser, so that we may update our records and avoid deleting your abstract from the program.

Please visit the [Congress website](#) to learn more.

Yours Sincerely,
ISID 2022 Kuala Lumpur Congress Secretariat

[Quoted text hidden]